Genmab reports 50% mortality cut in Phase 3 head‑and‑neck cancer trial
Genmab announced that its bispecific antibody petosemtamab, combined with pembrolizumab, cut the risk of death by half in patients with PD‑L1‑positive recurrent or metastatic head‑and‑neck squamous‑cell carcinoma. The interim analysis showed a hazard ratio of 0.50 and a statistically significant improvement in tumor response. The safety profile was unchanged from previous data, and the company said it will seek regulatory review and continue development.
Why it matters
The trial outcome provides a clear efficacy signal that could lead to regulatory approval and new revenue streams for Genmab. Analyst upgrades and higher price targets reflect expectations that the data will lift the company’s valuation.
Key facts
- 1The combination reduced death risk by 50% (hazard ratio 0.50, p<0.0001). investing.com
- 2Objective response odds ratio was 3.17, indicating stronger tumor shrinkage. investing.com
- 3The trial met both overall‑survival and response‑rate primary endpoints. rttnews.com
- 4No new safety signals were observed; the safety profile remained consistent with known data. investing.com
- 5JPMorgan upgraded Genmab to Overweight and raised its price target to DKK 3,500. investing.com
- 6TD Cowen lifted its price objective to $52.00 and kept a Buy rating. investing.com
Open questions
- Materials report different percentage gains for the stock: 16% (1), 16.8% (2), 15% (3), and 28.89% (4).
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.